Imaging synucleinopathies

Movement Disorders

Volumn 31, Issue 6, 2016, Pages 814-829

  Brooks, David J ^a,b,c   Tambasco, Nicola ^d  

^a AARHUS UNIVERSITY   (Denmark)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

DLB; MRI; MSA; Parkinson's; PET; SPECT

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALPHA SYNUCLEIN; DONEPEZIL;

COGNITION; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DOPAMINERGIC SYSTEM; EXECUTIVE FUNCTION; FUNCTIONAL NEUROIMAGING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASYMPATHETIC INNERVATION; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; SUSCEPTIBILITY WEIGHTED IMAGING; SYMPATHETIC INNERVATION; TREMOR; DIAGNOSTIC IMAGING; HUMAN; METABOLISM; PATHOLOGY; SHY DRAGER SYNDROME;

ALPHA-SYNUCLEIN; HUMANS; LEWY BODY DISEASE; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 84975690666     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26547     Document Type: Review

References (107)

1. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134.
2. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.
3. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996;47:1113-1124.
4. Armstrong RA, Cairns NJ, Lantos PL. Beta-amyloid deposition in the temporal lobe of patients with dementia with Lewy bodies: comparison with non-demented cases and Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11:187-192.
5. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-676.
6. Wenning GK, Jellinger KA. The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathol (Berl) 2005;109:129-140.
7. Savoiardo M, Girotti F, Strada L, Ciceri E. Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. J Neural Transm Suppl 1994;42:93-110.
8. Pujol J, Junque C, Vendrell P, Grau JM, Capdevila A. Reduction of the substantia nigra width and motor decline in aging and Parkinson's disease. Arch Neurol 1992;49:1119-1122.
9. Kosta P, Argyropoulou MI, Markoula S, Konitsiotis S. MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J Neurol 2006;253:26-32.
10. Wallis LI, Paley MN, Graham JM, et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 2008;28:1061-1067.
11. Lewis MM, Du G, Kidacki M, et al. Higher iron in the red nucleus marks Parkinson's dyskinesia. Neurobiol Aging 2013;34:1497-1503.
12. Ulla M, Bonny JM, Ouchchane L, Rieu I, Claise B, Durif F. Is R2* a new MRI biomarker for the progression of Parkinson's disease?. A longitudinal follow-up. PLoS One 2013;8:e57904.
13. Bunzeck N, Singh-Curry V, Eckart C, et al. Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease. Parkinsonism Relat Disord 2013;19:1136-1142.
14. Wieler M, Gee M, Martin WR. Longitudinal midbrain changes in early Parkinson's disease: iron content estimated from R2*/MRI. Parkinsonism Relat Disord 2015;21:179-183.
15. Bartzokis G, Cummings JL, Markham CH, et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging 1999;17:213-222.
16. Michaeli S, Oz G, Sorce DJ, et al. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord 2007;22:334-340.
17. Zhang W, Sun SG, Jiang YH, Qiao X, Sun X, Wu Y. Determination of brain iron content in patients with Parkinson's disease using magnetic susceptibility imaging. Neurosci Bull 2009;25:353-360.
18. Zhang J, Zhang Y, Wang J, et al. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study. Brain Res 2010;1330:124-130.
19. Dashtipour K, Liu M, Kani C, et al. Iron accumulation is not homogenous among patients with Parkinson's disease. Parkinsons Dis 2015;2015:324843.
20. Rossi M, Ruottinen H, Soimakallio S, Elovaara I, Dastidar P. Clinical MRI for iron detection in Parkinson's disease. Clin Imaging 2013;37:631-636.
21. Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP. The 'swallow tail' appearance of the healthy nigrosome-a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One 2014;9:e93814.
22. Blazejewska AI, Schwarz ST, Pitiot A, et al. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7T MRI. Neurology 2013;81:534-540.
23. Kwon DH, Kim JM, Oh SH, et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012;71:267-277.
24. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378-1384.
25. Zhang Y, Wu IW, Buckley S, et al. Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease. Mov Disord 2015;30:1229-1236.
26. Zhan W, Kang GA, Glass GA, et al. Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging. Mov Disord 2012;27:90-97.
27. Menke RA, Scholz J, Miller KL, et al. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage 2009;47:435-441.
28. Aquino D, Contarino V, Albanese A, et al. Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol Sci 2014;35:753-758.
29. Ofori E, Pasternak O, Planetta PJ, et al. Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study. Neurobiol Aging 2015;36:1097-1104.
30. Tambasco N, Pelliccioli GP, Chiarini P, et al. Magnetization transfer changes of grey and white matter in Parkinson's disease. Neuroradiology 2003;45:224-230.
31. Anik Y, Iseri P, Demirci A, Komsuoglu S, Inan N. Magnetization transfer ratio in early period of Parkinson disease. Acad Radiol 2007;14:189-192.
32. Tambasco N, Belcastro V, Sarchielli P, et al. A magnetization transfer study of mild and advanced Parkinson's disease. Eur J Neurol 2011;18:471-477.
33. Tambasco N, Nigro P, Romoli M, Simoni S, Parnetti L, Calabresi P. Magnetization transfer MRI in dementia disorders, Huntington's disease and parkinsonism. J Neurol Sci 2015;353:1-8.
34. Morgen K, Sammer G, Weber L, et al. Structural brain abnormalities in patients with Parkinson disease: a comparative voxel-based analysis using T1-weighted MR imaging and magnetization transfer imaging. AJNR Am J Neuroradiol 2011;32:2080-2086.
35. Konagaya M, Sakai M, Matsuoka Y, Goto Y, Yoshida M, Hashizume Y. Pathological correlate of the slitlike changes on MRI at the putaminal margin in multiple system atrophy. J Neurol 1999;246:142-143.
36. Schrag A, Kingsley D, Phatouros C, et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 1998;65:65-71.
37. Yekhlef F, Ballan G, Macia F, Delmer O, Sourgen C, Tison F. Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. J Neural Transm 2003;110:151-169.
38. von Lewinski F, Werner C, Jorn T, Mohr A, Sixel-Doring F, Trenkwalder C. T2*-weighted MRI in diagnosis of multiple system atrophy. A practical approach for clinicians. J Neurol 2007;254:1184-1188.
39. Focke NK, Helms G, Pantel PM, et al. Differentiation of typical and atypical Parkinson syndromes by quantitative MR imaging. AJNR Am J Neuroradiol 2011;32:2087-2092.
40. Eckert T, Sailer M, Kaufmann J, et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 2004;21:229-235.
41. Naka H, Imon Y, Ohshita T, et al. Magnetization transfer measurements of brain structures in patients with multiple system atrophy. Neuroimage 2002;17:1572-1578.
42. Reiter E, Mueller C, Pinter B, et al. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative parkinsonism. Mov Disord 2015;30:1068-1076.
43. Wang Y, Butros SR, Shuai X, et al. Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol 2012;33:266-273.
44. Gupta D, Saini J, Kesavadas C, Sarma PS, Kishore A. Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism. Neuroradiology 2010;52:1087-1094.
45. Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922-927.
46. Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002;58:575-580.
47. Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006;129(Pt 10):2679-2687.
48. Chung EJ, Kim EG, Bae JS, et al. Usefulness of diffusion-weighted MRI for differentiation between Parkinson's disease and Parkinson variant of multiple system atrophy. J Mov Disord 2009;2:64-68.
49. Seppi K, Schocke MF. An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr Opin Neurol 2005;18:370-375.
50. Blain CR, Barker GJ, Jarosz JM, et al. Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI. Neurology 2006;67:2199-2205.
51. Ji L, Wang Y, Zhu D, Liu W, Shi J. White matter differences between multiple system atrophy (parkinsonian type) and Parkinson's disease: a diffusion tensor image study. Neuroscience 2015;305:109-116.
52. Worker A, Blain C, Jarosz J, et al. Diffusion tensor imaging of Parkinson's disease, multiple system atrophy and progressive supranuclear palsy: a tract-based spatial statistics study. PLoS One 2014;9:e112638.
53. Savoiardo M, Strada L, Girotti F, et al. Olivipontocerebellar atrophy: MR diagnosis and relationship to multisystem atrophy. Radiology 1990;174:693-696.
54. Konayaga M, Konayaga Y, Iida M. Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. J Neurol Neurosurg Psychiatry 1994;57:1528-1531.
55. Schulz JB, Skalej M, Wedekind D, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999;45:65-74.
56. Matsui H, Nishinaka K, Oda M, Niikawa H, Kubori T, Udaka F. Dementia in Parkinson's disease: diffusion tensor imaging. Acta Neurol Scand 2007;116:177-181.
57. Duncan GW, Firbank MJ, Yarnall AJ, et al. Gray and white matter imaging: a biomarker for cognitive impairment in early Parkinson's disease? Mov Disord 2015 Jul 22. doi: 10.1002/mds.26312. [Epub ahead of print]
58. Zheng Z, Shemmassian S, Wijekoon C, Kim W, Bookheimer SY, Pouratian N. DTI correlates of distinct cognitive impairments in Parkinson's disease. Hum Brain Mapp 2014;35:1325-1333.
59. Fodero-Tavoletti MT, Mulligan RS, Okamura N, et al. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur J Pharmacol 2009;617:54-58.
60. Kikuchi A, Takeda A, Okamura N, et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 2010;133(Pt 6):1772-1778.
61. Claassen DO, Lowe VJ, Peller PJ, Petersen RC, Josephs KA. Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy. Parkinsonism Relat Disord 2011;17:160-165.
62. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003;184(Suppl 1):S68-S79.
63. Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005;128(Pt 12):2777-2785.
64. Goker-Alpan O, Masdeu JC, Kohn PD, et al. The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain 2012;135(Pt 8):2440-2448.
65. Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597-600.
66. Marek K, Seibyl JP, Zoghbi SS, et al. [I-123] beta-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemiparkinsons disease. Neurology 1996;46:231-237.
67. Morrish PK, Rakshi JS, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
68. Nicholl DJ, Vaughan JR, Khan NL, et al. Two large British kindreds with familial Parkinson's disease: a clinico-pathological and genetic study. Brain 2002;125(Pt 1):44-57.
69. Whone AL, Moore RY, Piccini P, Brooks DJ. Plasticity in the nigropallidal pathway in Parkinson's disease: an 18F-dopa PET study. Ann Neurol 2003;53:206-213.
70. Ponsen MM, Stoffers D, Booij J, Van Eck-Smit BL, Wolters E, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004;56:173-181.
71. Walker Z, Jaros E, Walker RW, et al. Dementia with lewy bodies: a comparison of clinical diagnosis, FP-CIT SPECT imaging and autopsy. J Neurol Neurosurg Psychiatry 2007;78:1176-1181.
72. Burn DJ, Sawle GV, Brooks DJ. The differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994;57:278-284.
73. Pirker W, Asenbaum S, Bencsits G, et al. [I-123]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000;15:1158-1167.
74. Brooks DJ, Playford ED, Ibanez V, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology 1992;42:1554-1560.
75. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT imaging: The [123I]-FP-CIT Study Group. Mov Disord 2000;15:503-510.
76. Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun 2006;27:933-937.
77. Marek K, Seibyl J, Eberly S, et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 2014;82:1791-1797.
78. Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994;44:1325-1329.
79. Turjanski N, Lees AJ, Brooks DJ. PET studies on striatal dopaminergic receptor binding in drug naive and L-dopa treated Parkinson's disease patients with and without dyskinesia. Neurology 1997;49:717-723.
80. Pavese N, Simpson BS, Metta V, Ramlackhansingh A, Chaudhuri KR, Brooks DJ. [(1)(8)F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [(1)(8)F]FDOPA and [(1)(1)C]DASB PET study in Parkinson's disease. Neuroimage 2012;59:1080-1084.
81. Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and PET. Ann Neurol 1992;31:184-192.
82. Schwarz J, Tatsch K, Gasser T, et al. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998;13:16-19.
83. Marek K, Innis R, van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-2094.
84. Parkinson, Group S. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480-1490.
85. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203-213.
86. Feigin A, Fukuda M, Dhawan V, et al. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 2001;57:2083-2088.
87. Lin TP, Carbon M, Tang C, et al. Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain 2008;131(Pt 5):1373-1380.
88. Hilker R, Voges J, Weisenbach S, et al. Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease. J Cereb Blood Flow Metab 2004;24:7-16.
89. Antonini A, Kazumata K, Feigin A, et al. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Mov Disord 1998;13:268-274.
90. Spetsieris PG, Ma Y, Dhawan V, Eidelberg D. Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. Neuroimage 2009;45:1241-1252.
91. Baggio HC, Segura B, Sala-Llonch R, et al. Cognitive impairment and resting-state network connectivity in Parkinson's disease. Hum Brain Mapp 2015;36:199-212.
92. Olde Dubbelink KT, Schoonheim MM, Deijen JB, Twisk JW, Barkhof F, Berendse HW. Functional connectivity and cognitive decline over 3 years in Parkinson disease. Neurology 2014;83:2046-2053.
93. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson's disease and serotonergic dysfunction: an (11)C-WAY 100635 PET study. Neurology 2003;60:601-605.
94. Loane C, Wu K, Bain P, Brooks DJ, Piccini P, Politis M. Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology 2013;80:1850-1855.
95. Qamhawi Z, Towey D, Shah B, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. Brain 2015;138(Pt 10):2964-2973.
96. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358-365.
97. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008;70(16 Pt 2):1470-1477.
98. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006;253:242-247.
99. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65:1716-1722.
100. Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res 2011;221:564-573.
101. Gilman S, Koeppe RA, Nan B, et al. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 2010;74:1416-1423.
102. Edison P, Rowe CC, Rinne J, et al. Amyloid load in Lewy body dementia (LBD), Parkinson's disease dementia (PDD) and Parkinson's disease (PD) measured with C-11-PIB PET. Neurology 2007;68:A98-A98.
103. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903-910.
104. Gomperts SN, Locascio JJ, Rentz D, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013;80:85-91.
105. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:249-251.
106. Druschky A, Hilz MJ, Platsch G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 2000;175:3-12.
107. Gjerloff T, Fedorova T, Knudsen K, et al. Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. Brain 2015;138(Pt 3):653-663.